CAPTRUST Financial Advisors’s Heron Therapeutics HRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$16.6K Buy
52,950
+1,403
+3% +$532 ﹤0.01% 3334
2026
Q2
$22K Buy
51,547
+4,266
+9% +$3.42K ﹤0.01% 3198
2026
Q1
$37.8K Buy
47,281
+5,691
+14% +$6.6K ﹤0.01% 2923
2025
Q4
$54.1K Sell
41,590
-7,366
-15% -$9.1K ﹤0.01% 2675
2025
Q3
$61.7K Buy
48,956
+1,335
+3% +$2.12K ﹤0.01% 2547
2025
Q2
$98.6K Buy
+47,621
New +$97.2K ﹤0.01% 2374
2024
Q1
– Sell
-51,102
Closed -$86.9K – 2381
2023
Q4
$86.9K Buy
51,102
+33,390
+189% +$36.8K ﹤0.01% 2542
2023
Q3
$18.2K Sell
17,712
-6,198
-26% -$8.82K ﹤0.01% 2524
2023
Q2
$27.7K Sell
23,910
-1,642
-6% -$2.93K ﹤0.01% 2452
2023
Q1
$38.6K Buy
+25,552
New +$64K ﹤0.01% 2226
2022
Q4
– Sell
-21,198
Closed -$89K – 2118
2022
Q3
$89K Buy
21,198
+20,631
+3,639% +$80.7K ﹤0.01% 1947
2022
Q2
$2K Sell
567
-518
-48% -$2.08K ﹤0.01% 4465
2022
Q1
$6K Buy
1,085
+564
+108% +$4.13K ﹤0.01% 4064
2021
Q4
$5K Sell
521
-370
-42% -$3.78K ﹤0.01% 4067
2021
Q3
$10K Sell
891
-103
-10% -$1.25K ﹤0.01% 3605
2021
Q2
$15K Buy
994
+504
+103% +$8.02K ﹤0.01% 3305
2021
Q1
$8K Buy
490
+390
+390% +$6.95K ﹤0.01% 3540
2020
Q4
$2K Hold
100
– – ﹤0.01% 3117
2020
Q3
$2K Sell
100
-100
-50% -$1.56K ﹤0.01% 2766
2020
Q2
$3K Buy
+200
New +$3.29K ﹤0.01% 2511
2019
Q4
– Sell
-1,396
Closed -$26K – 1358
2019
Q3
$26K Buy
1,396
+1,196
+598% +$22K ﹤0.01% 1223
2019
Q2
$4K Hold
200
– – ﹤0.01% 1694
2019
Q1
$5K Hold
200
– – ﹤0.01% 1526
2018
Q4
$5K Hold
200
– – ﹤0.01% 1327
2018
Q3
$6K Buy
+200
New +$7.45K ﹤0.01% 1330

Other funds holding HRTX

CAPTRUST Financial Advisors's HRTX Position: Q3 2026 in Review

CAPTRUST Financial Advisors increased its Heron Therapeutics (HRTX) stake by 2.7% in Q3 2026, buying an estimated $532 and bringing the position to 52,950 shares worth $16.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3334.

CAPTRUST Financial Advisors first reported a position in HRTX in Q3 2018 and has held it in 25 quarters since. The position peaked at $98.6K in Q2 2025. 158 funds tracked by Wall St. Rank hold HRTX as of Q3 2026.

  • CAPTRUST Financial Advisors held 52,950 shares of Heron Therapeutics worth $16.6K as of Q3 2026.
  • CAPTRUST Financial Advisors bought 1,403 Heron Therapeutics shares in Q3 2026, an estimated $532.
  • Heron Therapeutics made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q3 2026, its #3334 holding.
  • CAPTRUST Financial Advisors first reported a position in Heron Therapeutics in Q3 2018 and has held it in 25 quarters since.
  • CAPTRUST Financial Advisors's Heron Therapeutics position peaked at $98.6K in Q2 2025.
  • 158 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2026, filed 12 Nov 2026.